New approved treatment for wet AMD

Lytenava (bevacizumab gamma), is the first licensed version of Avastin for wet age-related macular degeneration. The treatment was approved by the National Institute for Health and Care Excellence (NICE) for use in the NHS last year.

Professor Andrew Lotery joins our webinar to break down what this new treatment means for you. He’ll also discuss how Lytenava compares to existing treatments, such as Eylea and Lucentis, its potential benefits, and what this approval means for NHS patients.